...
首页> 外文期刊>OncoTargets and therapy >Effects of thyrotropin suppression on lumber bone mineral density in postmenopausal women with differentiated thyroid carcinoma
【24h】

Effects of thyrotropin suppression on lumber bone mineral density in postmenopausal women with differentiated thyroid carcinoma

机译:促甲状腺激素抑制对绝经后分化型甲状腺癌妇女木材骨矿物质密度的影响

获取原文

摘要

Purpose: The aim of this study was to evaluate the effect of postoperative thyroid-stimulating hormone suppression (TSHS) on bone mineral density (BMD) in Chinese postmenopausal women with differentiated thyroid carcinoma (DTC). Patients and methods: A total of 225 postmenopausal women with DTC who had received TSHS were included in the study. Postmenopausal women with postoperative DTC undergoing thyroid residual ablation or metastasis treatment between 2009 and 2015 were enrolled and followed up for 2 years. They were divided into two groups: TSHS group (median thyroid-stimulating hormone [TSH] -2.5 SD) and osteoporosis (T -2.5 SD) was made according to WHO guidelines. Results: Thyroid cancers included 211 papillary carcinomas and 14 follicular carcinomas. One hundred and fifty-four patients were in the TSHS group, and 71 patients were in the non-suppressed TSH group (postmenopausal controls). No significant differences were found in the BMD of the lumbar spine between baseline and after 6, 12 and 24 months, pre and post treatment in TSHS and non-suppressed TSH patients. Compared with pre-TSHS, there was a reduction in the BMD of 1.9% in the lumbar spine at the 2-year follow-up. Significant difference in the number of osteopenia and osteoporosis patients at 24 months ( χ 2=2.88, P =0.004) was found between the TSHS (103/152) and postmenopausal control (32/68) groups. TSHS is not a significant risk of bone loss, but it is the incidence of osteopenia in postmenopausal women with DTC. Conclusion: Our 2-year follow-up data indicated that TSHS had little effect on BMD in postmenopausal women with DTC. Large population with at least 5-year follow-up should be further investigated. BMD in postmenopausal women with DTC should be followed up regularly.
机译:目的:本研究旨在评估中国绝经后分化型甲状腺癌(DTC)妇女术后甲状腺刺激激素抑制(TSHS)对骨矿物质密度(BMD)的影响。患者和方法:本研究共纳入了225名接受TSHS的绝经后DTC妇女。纳入2009年至2015年间接受甲状腺残留消融或转移治疗的术后DTC绝经后妇女,并随访2年。将它们分为两组:TSHS组(中位甲状腺刺激激素[TSH] -2.5 SD)和骨质疏松症(T <-2.5 SD)是根据WHO指南制定的。结果:甲状腺癌包括211例乳头状癌和14例滤泡状癌。 TSHS组中有154例患者,TSH未抑制组(绝经后对照)中有71例患者。在TSHS和未抑制的TSH患者中,治疗前后,治疗前后6个月,12个月和24个月后,腰椎的BMD均无显着差异。与TSHS之前相比,在两年的随访中,腰椎的BMD降低了1.9%。 TSHS(103/152)和绝经后对照组(32/68)组在24个月时骨质疏松症和骨质疏松症患者的数量有显着差异(χ2 = 2.88,P = 0.004)。 TSHS并不是造成骨质流失的重大风险,但它是绝经后患有DTC的女性骨质减少的发生率。结论:我们的2年随访数据表明,TSHS对绝经后DTC妇女的BMD影响不大。至少随访5年的大量人群应进一步调查。绝经后患有DTC的女性应定期随访BMD。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号